Roberts Pharmaceuticals

Roberts Pharmaceuticals was a specialty pharmaceutical company that focused on the acquisition, development, and commercialization of niche prescription drugs. The company's strategy involved identifying under-promoted or late-stage products from larger pharmaceutical firms and maximizing their value through targeted marketing and further clinical development. Its portfolio spanned several therapeutic areas, including oncology, gastroenterology, and respiratory medicine, with key products such as Agrylin and ProAmatine. In late 1999, the company was acquired by Shire Pharmaceuticals Group in a stock-for-stock transaction valued at approximately $1 billion. This acquisition significantly bolstered Shire's US commercial infrastructure and product pipeline. At the time of its acquisition, Roberts was recognized for its successful track record in navigating the regulatory and commercial challenges of specialty medicine.